Volition is a multi-national epigenetics company developing simple, easy to use, costeffective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of NucleosomicsTM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.
Company profile
Ticker
VNRX
Exchange
Website
CEO
Cameron John Reynolds
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
STANDARD CAPITAL CORP
SEC CIK
Corporate docs
Subsidiaries
Singapore Volition Pte. Limited • Belgian Volition SRL • Volition Diagnostics UK Limited • Volition America, Inc. • Volition Veterinary Diagnostics Development LLC. • Volition Germany GmbH • Volition Global Services SRL ...
IRS number
911949078
VNRX stock data
Latest filings (excl ownership)
10-K
2022 FY
Annual report
15 Mar 23
8-K
VolitionRx Limited Announces Full Fiscal Year 2022 Financial Results and Business Update
15 Mar 23
8-K
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock
21 Feb 23
424B5
Prospectus supplement for primary offering
21 Feb 23
424B5
Prospectus supplement for primary offering
16 Feb 23
8-K
Departure of Directors or Certain Officers
25 Nov 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
VolitionRx Limited Announces Third Quarter 2022 Financial Results and Business Update
14 Nov 22
S-8
Registration of securities for employees
30 Sep 22
8-K
Volition Appoints Mickie Henshall as an Independent Director
16 Aug 22
Transcripts
VNRX
Earnings call transcript
2022 Q4
16 Mar 23
VNRX
Earnings call transcript
2022 Q3
15 Nov 22
VNRX
Earnings call transcript
2022 Q2
13 Aug 22
VNRX
Earnings call transcript
2022 Q1
12 May 22
VNRX
Earnings call transcript
2021 Q4
31 Mar 22
VNRX
Earnings call transcript
2021 Q3
13 Nov 21
VNRX
Earnings call transcript
2021 Q2
12 Aug 21
VNRX
Earnings call transcript
2021 Q1
12 May 21
VNRX
Earnings call transcript
2020 Q4
23 Mar 21
VNRX
Earnings call transcript
2020 Q3
16 Nov 20
Latest ownership filings
4
Guy Archibald Innes
23 Feb 23
SC 13G/A
Lagoda Investment Management, L.P.
14 Feb 23
4
Rodney Gerard Rootsaert
13 Jan 23
4
Salvatore Thomas Butera
13 Jan 23
4
Terig Hughes
13 Jan 23
4
Richard Brudnick
13 Jan 23
4
Phillip Barnes
13 Jan 23
4
Nicholas Plummer
13 Jan 23
4
Alan Colman
13 Jan 23
4
Martin Charles Faulkes
13 Jan 23
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 10.87 mm | 10.87 mm | 10.87 mm | 10.87 mm | 10.87 mm | 10.87 mm |
| Cash burn (monthly) | 1.85 mm | 809.52 k | 2.67 mm | 2.65 mm | 1.73 mm | 1.27 mm |
| Cash used (since last report) | 5.09 mm | 2.23 mm | 7.35 mm | 7.29 mm | 4.76 mm | 3.51 mm |
| Cash remaining | 5.77 mm | 8.64 mm | 3.51 mm | 3.57 mm | 6.11 mm | 7.36 mm |
| Runway (months of cash) | 3.1 | 10.7 | 1.3 | 1.3 | 3.5 | 5.8 |
Institutional ownership, Q3 2022
30.7% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 34 |
| Opened positions | 7 |
| Closed positions | 5 |
| Increased positions | 8 |
| Reduced positions | 6 |
| 13F shares | Current |
|---|---|
| Total value | 44.48 mm |
| Total shares | 17.83 mm |
| Total puts | 32.80 k |
| Total calls | 106.00 k |
| Total put/call ratio | 0.3 |
| Largest owners | Shares | Value |
|---|---|---|
| Eight | 12.05 mm | $36.62 mm |
| Lagoda Investment Management | 3.26 mm | $4.43 mm |
| BLK Blackrock | 537.94 k | $732.00 k |
| Vanguard | 503.27 k | $685.00 k |
| MS Morgan Stanley | 378.35 k | $515.00 k |
| Geode Capital Management | 288.36 k | $392.00 k |
| Bank Julius Baer & Co. Ltd, Zurich | 147.63 k | $201.00 k |
| Bridgeway Capital Management | 126.10 k | $171.00 k |
| Citadel Advisors | 103.88 k | $141.00 k |
| Cowen Prime Advisors | 96.63 k | $131.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 22 Feb 23 | Innes Guy Archibald | Common Stock | Buy | Acquire P | Yes | No | 1.75 | 58,500 | 102.38 k | 154,504 |
| 22 Feb 23 | Innes Guy Archibald | Common Stock | Buy | Acquire P | Yes | No | 1.75 | 58,500 | 102.38 k | 154,504 |
| 22 Feb 23 | Innes Guy Archibald | Common Stock | Buy | Acquire P | Yes | No | 1.75 | 58,500 | 102.38 k | 154,503 |
| 22 Feb 23 | Innes Guy Archibald | Common Stock | Buy | Acquire P | Yes | No | 1.75 | 58,500 | 102.38 k | 154,503 |
| 12 Jan 23 | Reynolds Cameron John | Common Stock | Grant | Acquire A | No | No | 0 | 33,375 | 0.00 | 1,444,468 |
| 12 Jan 23 | Ann-Louise Batchelor | Common Stock | Grant | Acquire A | No | No | 0 | 14,625 | 0.00 | 40,358 |
| 12 Jan 23 | Innes Guy Archibald | Common Stock | Grant | Acquire A | No | No | 0 | 5,625 | 0.00 | 1,570,411 |
| 12 Jan 23 | Michel Gaetan | Common Stock | Grant | Acquire A | No | No | 0 | 27,750 | 0.00 | 174,697 |
Press releases
VolitionRx Limited Announces Full Fiscal Year 2022 Financial Results and Business Update
15 Mar 23
VolitionRx Limited Schedules Full Year 2022 Earnings Conference Call and Business Update
10 Mar 23
VolitionRx Limited to Webcast Live at VirtualInvestorConferences.com March 9th
6 Mar 23
VolitionRx Limited Announces Closing of $8.7 Million Underwritten Public Offering of Common Stock
22 Feb 23
VolitionRx Limited Announces Pricing of $7.525 Million Underwritten Public Offering of Common Stock
17 Feb 23